x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

40:21

259: The FTC v. Amgen, Sarepta's future, & Galapagos'...

The Readout Loud ·

2023/05/18

Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen's $28 billion merger with Horizon Therapeutics and what it means for the drug industry. We also discuss the latest on Sarepta Therapeutics and its gene therapy for Duchenne muscular dystrophy, a turnaround story in the making at the Belgian drug maker Galapagos, and the effort to secure approval for a maternal RSV vaccine.

en

31:47

258: Pharma vs. PBMs, Sarepta at the FDA, & a bold...

The Readout Loud ·

2023/05/11

We discuss a Senate hearing that put major pharma CEOs in the same room with the middlemen they love to blame for rising drug prices, with mixed results. We also explain what is a massive week for Sarepta Therapeutics, the FDA, and the future of gene therapies for rare diseases, plus the latest news in the life sciences.

en

34:58

257: Lilly's Alzheimer's success, a milestone FDA...

The Readout Loud ·

2023/05/04

Eli Lilly’s investigational medicine for Alzheimer’s met its goals in an all-important clinical trial, and we explain the results, their implications, and the backstory of what could be a blockbuster drug. We also discuss the latest news in the life sciences, including a busy week of earnings, a long-awaited FDA approval, and the highlights from STAT’s Breakthrough Summit in San Francisco.

en

28:58

256: Explaining the E.U.'s pharma overhaul, Lilly's...

The Readout Loud ·

2023/04/27

Andrew Joseph, STAT's Europe correspondent, joins us to explain the EU's sweeping proposal to overhaul how new drugs are regulated on the continent — and why the pharmaceutical industry is fighting it. We also discuss the latest news in the life sciences, including Lilly's surging business, a pair of new drug approvals, and a novel idea in Alzheimer's disease.

en

39:07

255: Sarepta's pivotal moment, biotech's big week, &...

The Readout Loud ·

2023/04/20

Our colleague Helen Branswell joins us to explain the latest news on Covid-19 boosters and the implications of a Marburg outbreak in Equatorial Guinea. Then we dive into the long history of a gene therapy from Sarepta Therapeutics, a polarizing medicine that promises to change the lives of patients with Duchenne muscular dystrophy. We also break down the rest of the week’s biggest news in biopharma, including some billion-dollar deals and the retirement of perhaps the most storied executive in the

en

40:01

254: The legal battle over abortion, an FDA 'bully...

The Readout Loud ·

2023/04/13

Jeremy Levin, CEO of Ovid Therapeutics, joins us to discuss a judge’s decision to overturn the FDA approval of an abortion pill and why he believes it’s the biggest threat to the biopharma industry in 50 years. We also cover the biggest news in the week of biopharma, including an update from Moderna, dispatches from a trip to FDA headquarters, and who Sen. Bernie Sanders has in his sights next.

en

36:08

253: Illumina’s boardroom intrigue, the next big...

The Readout Loud ·

2023/04/06

Our colleague Matthew Herper joins us for a deep dive into Illumina, explaining how the biggest company in genome sequencing lost the faith of shareholders and painted itself into a corner. We’ll also discuss the latest news in the life sciences, including a look at what’s ahead in biotech for the second quarter of the year, and why Johnson & Johnson investors are happy the company is proposing to part with $9 billion.

en

36:00

252: Biotech's monkey shortage, the broken generics...

The Readout Loud ·

2023/03/30

We explain how biotech is affected by a bizarre situation involving smuggled monkeys, international intrigue, and a criminal investigation. We also discuss what leads to generic drug shortages, whether every major pharmaceutical firm needs a weight-loss drug, and what it means when drug company cancels a conference appearance.

en

34:22

251: Bancel v. Bernie, Sarepta's FDA runaround, &...

The Readout Loud ·

2023/03/23

We discuss the theatrical merits and actual implications of Moderna CEO Stéphane Bancel's appearance before a committee led by Sen. Bernie Sanders. We also talk about the latest news in the life sciences, including Regeneron Pharmaceuticals' latest data for its powerhouse drug Dupixent, an about-face for Sarepta Therapeutics, and how the FDA appears to view biomarkers in neurological diseases.

en

35:48

250: SVB's long biotech shadow, pushy AI algorithms,...

The Readout Loud ·

2023/03/16

STAT reporter Bob Herman joins us to explain how treatment algorithms powered by artificial intelligence are being used more frequently by Medicare Advantage plans to deny claims, even when continued treatment is medically justified. We’ll also discuss the latest news in the life sciences, including the continued fallout of the run on Silicon Valley Bank, the return of Carl Icahn, and a long-awaited pharmaceutical megadeal.

en

38:00

249: Robert Califf on how drugs get approved, plus...

The Readout Loud ·

2023/03/09

FDA Commissioner Robert Califf joins to discuss his first year on the job, the future of drug approvals, and how Duke basketball will do without Coach K. Then STAT’s Elaine Chen explains how powerful new weight loss medicines are reshaping medicine, the drug industry, and the society at large. We also discuss the latest news in the life sciences, including the results of a new Alzheimer's disease study and a potential breakthrough in cardiovascular medicine.

en

28:36

248: The next CRISPR fight, cheaper insulin, & an FDA...

The Readout Loud ·

2023/03/02

Our colleague Allison DeAngelis joins us to explain how the latest CRISPR breakthrough is shaping up to be a free-for-all among a multitude of companies and labs, including some of the biggest names in biotech. We also discuss the latest news in the life sciences, including Eli Lilly slashing the cost of insulin, succession at the FDA, and how pandemic boom times have turned to bust.

en

38:07

247: Vertex vs. insurers, Moderna's future, &...

The Readout Loud ·

2023/02/23

STAT’s Ed Silverman joins us to explain how an escalating fight between Vertex Pharmaceuticals and insurance companies has left patients and families caught in the middle. We also discuss the latest news in the life sciences, including the demise of a one-time unicorn, Moderna’s difficult second act, and an official biotech presidential run.

en

40:04

246: Vas Narasimhan on the future of pharma, plus...

The Readout Loud ·

2023/02/16

Vas Narasimhan, CEO of Novartis and the new chairman of PhRMA, joins us to discuss the industry’s struggles in Washington and whether the deflated biotech sector is still overvalued. We also dive into the latest news in the life sciences, including Moderna's promise of no-cost Covid-19 vaccines and biotech entrepreneur Vivek Ramaswamy's potential run for president.

en

20:53

245: The return of bird flu and the effects of...

The Readout Loud ·

2023/02/09

Helen Branswell, STAT’s senior writer covering infectious disease, joins us to explain the sudden resurgence of a bird flu virus called H5N1 and why experts are watching the situation closely.

en

35:29

244: Pharma blockbusters, pandemic policy, & legal...

The Readout Loud ·

2023/02/02

STAT Washington correspondent Rachel Cohrs joins us to explain the looming end of Covid-19's status as a federal emergency and what that does and doesn't mean for public health. We also dig into the most interesting stories from a busy week of pharmaceutical earnings and discuss a legal setback for Johnson & Johnson.

en

31:35

243: George Scangos' retirement, annual Covid...

The Readout Loud ·

2023/01/26

George Scangos, the CEO of Vir Biotechnology, joins us to discuss his retirement and offer some perspective and lessons from a remarkable, 40-year career in biotech. We also chat about the latest news in the life sciences, including an FDA advisory meeting debating the necessity for annual Covid vaccinations, and a surprising, but perhaps not, rejection of Eli Lilly’s Alzheimer’s disease treatment.

en

32:27

242: How blockbusters get made, new vaccines for RSV,...

The Readout Loud ·

2023/01/19

Journalist Nathan Vardi joins us to talk about his new book delving into the race to develop the lifesaving cancer drug now called Imbruvica, involving a Scientologist CEO and secretive investor seeking redemption after the worst trade of his life. We also discuss the latest news in the life sciences, including new vaccines for a vexing infection and the future of mRNA.

en

32:46

241: #JPM23 in review, the year ahead, & the merits...

The Readout Loud ·

2023/01/12

With the 2023 J.P. Morgan Healthcare Conference drawing to a close, we look back on the biggest news of the meeting, what it means for the year in biotech ahead, and whether the industry's biggest annual gathering might finally have outgrown its host city.

en

36:05

240: #JPM23, the future of Alzheimer's, & rising...

The Readout Loud ·

2023/01/05

First, we delve into a sweeping congressional investigation into the FDA's approval of the last treatment for Alzheimer's disease and what it means for the next one. We also preview the upcoming J.P. Morgan Healthcare Conference and the biggest biotech events of 2023.

en

381 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...